Earnings Scheduled For November 10, 2021
Companies Reporting Before The Bell
• LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.
Lineage Cell Therapeutics Earnings Perspective: Return On Capital Employed
Lineage Cell Therapeutics (AMEX:LCTX) brought in sales totaling $512.00 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 0.43%, resulting in a loss of $7.08 million.
From BZ’s Small Cap Healthcare Conference: Lineage Cell Therapeutics CEO, Brian M. Culley Begins Speaking
Click To Tune In Here... https://www.youtube.com/watch?v=KJGuHiRQ4wE
New OpRegen® Clinical Data Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.
Statistically Significant Evidence of a Treatment Effect with OpRegen Observed in Cohort 4 Patients
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing
53 Biggest Movers From Yesterday
Gainers
DICE Therapeutics, Inc. (NASDAQ: DICE) shares surged 117% to settle at $36.89 on Wednesday as the company priced its IPO at $17 per share.
38 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Indaptus Therapeutics, Inc. (NASDAQ: INDP) shares jumped 177.2% to $19.60 after the company announced the United States Patent and Trademark Office has issued a notice of allowance for claims related to the company's platform technology.
Lineage Cell Therapeutics Reports Updated Interim Results From Ongoing, 24-Patient Phase 1/2a Trial Of Its OpRegen
First Reported Case of Retinal Tissue Restoration Showed Zero Growth of Atrophy at 33 Months
Second Case of Retinal Tissue Restoration Exhibited a 10% Reduction in Atrophy Size at 8 Months
Third Case of Retinal
Noble Capital Markets Initiates Coverage On Lineage Cell Therapeutics with Outperform Rating, Announces Price Target of $8
Noble Capital Markets analyst Robert LeBoyer initiates coverage on Lineage Cell Therapeutics (AMEX:LCTX) with a Outperform rating and announces Price Target of $8.
Lineage Cell Therapeutics Q2 EPS $(0.03) Beats $(0.04) Estimate, Sales $500.00K Beat $480.00K Estimate
Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.04) by 25 percent. This is a 25 percent increase over losses of $(0.04) per share from
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 11)